Type 2 diabetes
Conditions
Interventions
dapaglifrogine 5-10mg/day for 24weeks
metoformine 500-1500mg/day for 24weeks
Sponsors
Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Outpatients diagnosed with type 2 diabetes, aged 20-75years old 2)Patients treated with diet therapy and execise therapy for 2months, and did not treated with metoformine or dapaglifrogine 3)Patients treated with oral hypoglycemic agent within 2 drags. 4)glycemic control: HbA1c >=7.0%,=<10.0% 5)Having provided voluntary written consent for participation in this study.
Exclusion criteria
Exclusion criteria: 1)Patients diagnosed with Type 1 diabetes or secondary forms of diabetes 2)Patients with renal dysfunction (eGFR <45ml/min/1.73m2) 3)Patients with hepatic dysfunction(AST and/or ALT >3X upper limit of normal) 4)Patients with severe congestive heart failure, acute heart failure 5)Patients who are taking steroid medication 6) Patients with a history of diabetic ketoacidosis, diabetic coma during the last 6 months 7)Patients with active malignant neoplasm 8)Patients with severe infection or injury 9)Patients with hypersensitivity to metoformine or dapaglifrogine 10) Patients who are pregnant,lactating or willing to be pregnant during this study 11) Patients who have taken SGLT2 or metoformine within 8 weeks prior to enroll, or who are already taking SGLT2 or metoformine 12)Patients who are unable to obtain informed consent to this study 13)Patients who are inadequacy of using this therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement in HbA1c after 24 weeks of treatment. | — |
Countries
Japan
Contacts
Public ContactYuzuru Ito
Yokohama City University Department of Endocrinology and Metabolism
Outcome results
None listed